Format

Send to

Choose Destination
AIDS. 2020 Jan 1;34(1):103-108. doi: 10.1097/QAD.0000000000002372.

Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.

Author information

1
Service of Clinical Pharmacology, University Hospital of Lausanne and University of Lausanne, Lausanne.
2
Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel.
3
University of Basel, Basel.
4
Institute of Pharmaceutical Sciences of Western Switzerland, Geneva.
5
Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Abstract

OBJECTIVES:

The pharmacokinetics of antiretroviral drugs may differ in elderly people living with HIV (PLWH) because of age-related physiological changes. We aimed to assess the pharmacokinetics of several antiretroviral drugs in aging PLWH enrolled in the Swiss HIV Cohort (SHCS).

DESIGN:

Full pharmacokinetic profiling nested in a multicenter, observational, prospective cohort study. Additional collection of single point pharmacokinetic data during SHCS follow-up visits (unselected PLWH).

METHODS:

PLWH were eligible for the full pharmacokinetics investigation if they were over the age of 55 years, on a stable boosted darunavir-containing or dolutegravir-containing regimen. Single point measurements were prospectively collected during SHCS follow-up visits to compare antiretroviral drug exposure in aging (≥65 years) and younger (<65 years) PLWH.

RESULTS:

Nineteen PLWH with a median age of 64 years participated in the full pharmacokinetic investigations. Single point pharmacokinetic data were collected for 804 PLWH with a median age of 52 years. Boosted darunavir clearance was 40% lower in aging (≥65 years) compared with younger (<65 years) PLWH, consistent with other drugs predominantly metabolized by CYP3A. Dolutegravir exposure was similar between age groups whereas lamivudine exposure increased by 11% in aging PLWH. Median boosted darunavir, dolutegravir and lamivudine t1/2 were 148%, 45% and 32% higher in aging compared with younger PLWH.

CONCLUSION:

Advanced age did not affect boosted darunavir exposure to a clinically significant extent despite the observed high variability in exposure. Age minimally affected dolutegravir and lamivudine exposure. Thus, dose adjustment based on age is a priori not warranted.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center